Median Technologies Partners with a Top 10 Oncology Pharma Company to Apply AI for Imaging Biomarker Discovery
07 August 2024 - 1:45AM
Business Wire
- The partnership’s aim is to identify predictive imaging
biomarkers of patient response to a specific drug-candidate, using
Imaging Lab’s unique AI capabilities.
- The company is a Top 10 global oncology pharmaceutical
company.
- Imaging Lab is a division of iCRO, launched in 2022, that
applies Artificial Intelligence (AI), Machine Learning (ML),
radiomics and data mining, to extract insights from clinical trial
images.
- Following the agreement with a Top 3 pharmaceutical company
announced in May 2024, this partnership highlights Median’s
competitive advantage with AI-driven imaging technologies for
clinical trials.
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/PME scheme
eligible, “Median” or “The Company”) announces today it has signed
an initial agreement with a Top 10 oncology pharmaceutical
company1. The agreement aims at conducting AI-based imaging
biomarker2 discovery on the clinical data of a drug candidate. The
agreement could lead to a broader collaboration between the
pharmaceutical company and Median.
The agreement involves Imaging Lab, a dedicated entity of
Median’s iCRO Business Unit. Imaging Lab provides biopharma
companies with advanced AI-based decision-making capabilities,
leveraging patients’ imaging data to provide specific patient
selection, prediction of response to therapy, accurate monitoring
of disease progression, and early access to safety and
efficacy.
Median will apply its unique expertise, methods, and know-how in
AI-based technologies to identify specific digital signatures
(imaging biomarkers) from images, providing meaningful information
on the drug responder/non-responder status of the patients. The
drug-specific imaging biomarkers could ultimately be utilized as
companion diagnostics3 to select patients who are most likely to
benefit from the drug.
Fredrik Brag, CEO and Founder of Median Technologies,
highlighted: “We recently announced the selection of Median as
preferred provider to a second global Top 3 pharmaceutical group.
We are thrilled to announce today the launch of a collaboration
with a global Top 10 pharma to support a drug development program
with our AI-driven imaging technologies. Pharmaceutical companies
are early adopters of AI in their drug development plans and
investment in AI by large pharma is growing at a steady pace,
creating very positive momentum for Median as a unique AI
technology company in the imaging CRO market. AI is now everywhere
in drug development and the AI in clinical trials market is
expected to reach $6.55 Billion by 20304. AI-driven imaging
technologies applied to clinical trials unveil new insights that
could determine the success of oncology trials. Providing insights
for ‘Go/No-Go’ decisions at an early stage, or to discover
predictive imaging biomarkers of patient response to drug
candidates are two of the most compelling outcomes. Imaging AI
solutions will become the new generation of companion diagnostics,
opening unique opportunities in the era of precision medicine.”
Nicolas Dano, COO & CCO iCRO said: “AI-driven imaging
insights are the future in oncology drug development. As a native
technology company, Median is the only imaging CRO that has AI
know-how and experience, giving us a unique competitive advantage
to penetrate the Big Pharma market. We are eager to start the
collaboration and provide valuable insights to our new partner,
helping them with their drug development plans.”
About Median Technologies: Pioneering innovative imaging
solutions and services, Median Technologies harnesses cutting-edge
AI to enhance the accuracy of early cancer diagnoses and cancer
treatments. Median's offerings, including iCRO for medical image
analysis and management in oncology trials and eyonis™, AI/ML
tech-based suite of software as medical devices (SaMD), empower
biopharmaceutical entities and clinicians to advance patient care
and expedite novel therapies. The French-based company, with a
presence in the U.S. and China, trades on the Euronext Growth
market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for
the French SME equity savings plan scheme (PEA-PME). For more
information: www.mediantechnologies.com
1 Arjun Murthy – Top 15 biopharma companies by Oncology Sales in
2023 2 An imaging biomarker is a “defined characteristic that is
measured as an indicator of normal biological processes, pathogenic
processes or responses to an exposure or intervention, including
therapeutic interventions” -
https://www.ncbi.nlm.nih.gov/books/NBK326791/ 3
https://www.fda.gov/medical-devices/in-vitro-diagnostics/companion-diagnostics
4 Explosive Growth Forecasted: AI in Clinical Trials Market Set
(openpr.com)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240806313597/en/
Median Technologies Emmanuelle Leygues Head of Corporate
Marketing & Financial Communications +33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com
Press - ALIZE RP Caroline Carmagnol +33 6 64 18 99 59
median@alizerp.com
Investors - ACTIFIN Ghislaine Gasparetto +33 6 21 10 49
24 ghislaine.gasparetto@seitosei-actifin.com
Median Technologies (EU:ALMDT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Median Technologies (EU:ALMDT)
Historical Stock Chart
From Sep 2023 to Sep 2024